Results 181 to 190 of about 7,765,653 (401)
St John's Wort users reported: a history of exposure to herbal remedies and belief in their safety; depressed mood; and ease of access to alternative medicines [PDF]
R. L Bashore
openalex +1 more source
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi+12 more
wiley +1 more source
Antioxidants in the Finnish press: a battlefield of alternative and conventional medicine [PDF]
Liisa Uusitalo
openalex +1 more source
Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza+3 more
wiley +1 more source
Alternative Therapies and Medical Science: Designing Clinical Trials of Alternative/Complementary Medicines—Is Evidence‐Based Traditional Chinese Medicine Attainable? [PDF]
Julia Critchley+4 more
openalex +1 more source
Kava - the unfolding story: Report on a work-in-progress. [PDF]
Journal of Alternative and Complementary Medicine, 8(3), 237 ...
Denham, Alison+2 more
core
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh+5 more
wiley +1 more source
Congressional Committee Explores Alternative Medicine And Women's Cancers
S. Poer, Steven R. Erickson
openalex +1 more source
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha+10 more
wiley +1 more source
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham+21 more
wiley +1 more source